Direct Interstitial Decongestion in an Animal Model of Acute-on-Chronic Ischemic Heart Failure

Figures

• 

  Figure 1. First-Generation Whiteswell Catheter See text for description.

• 

  Figure 2. Extravascular Lung Water Changes (Top) Changes in the estimated extravascular lung water content (EVLW) as measured in sheep with induced acute decompensation (ADHF) both before and during treatment with the WhiteSwell device (left). Changes in time-matched untreated controls (CTRL) are shown (right) for comparison. (Bottom) Absolute and/or relative changes post-treatment in EVLW (mL/kg), arterial oxygen tension (PaO2), left-ventricular filling pressures (EDP), and cardiac output (CO).

• 

  Figure 3. Clinical Case Example With Whiteswell Treatment During WhiteSwell treatment, urine output increased (yellow). Comparing post-therapy to pretreatment, the central venous pressure decreased from 17 mm Hg to 3 mm Hg, and creatinine levels fell slightly (blue dots).

• 

  Figure 4. Lymphatic System and Thoracic Duct Function in Healthy Individuals and in Acute Decompensated Heart Failure (A and B) Normal thoracic duct function and lymph formation. (C and D) Pathological changes in thoracic duct function and lymph formation in the setting of acute decompensated heart failure (ADHF). (E) Thoracic duct decompression and restoration of lymph flow during treatment with the WhiteSwell device. See text for detailed explanations. Figure by Avesta Rastan.